Fig 1.
42 villages from 5 districts surveyed in the province of Cabo Delgado, northern Mozambique.
We created the map using QGIS and publicly available shapefiles from http://www.diva-gis.org/gdata.
Fig 2.
Distribution of height and weight measurements from the Mozambique study population (n = 9,827).
Table 1.
Demography of 9,827 individuals surveyed in northern Mozambique, by gender and age group, who received treatment with praziquantel doses below, within, or above the recommended amounts using the current WHO dose pole.
Table 2.
Modeling of the likelihood of underdosing based on binomial generalized linear mixed model (GLMM), considering gender and age groups as variables.
Table 3.
The percentage of adults surveyed in northern Mozambique, by gender and age, who were classified as overweight/obese based on body mass index values > 25.0.
Table 4.
The accuracy of the WHO standard dose pole compared to the modified-format dose pole, with or without BMI adjustment, in determining praziquantel doses for the 2,231 adults surveyed in northern Mozambique.
Table 5.
GLMM analysis to compare the odds of insufficient dosing (< 30mg/Kg of praziquantel) using the WHO dose pole vs the modified dose pole for adults in Mozambique.
Fig 3.
Current WHO-dose pole format (A), the extended dose pole for infants and PSAC proposed by Sousa-Figueiredo et al. [22] (B), the modified dose pole for adult treatment proposed by Palha de Sousa et al. [14] (C), and a universal dose pole for schistosomiasis treatment at all age groups (D).